Subtype
Hepatopancreatobiliary Carcinoma
CI-CAN-00002859Explore in graph →
1,361 active trials21 approved drugs69 evidence items
- NCIt
- C214986
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002859Explore in graph →
Clinical trials
5,154 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (647)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05733598 | Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC | recruiting | Phase 2 | 60 | Replimune, Inc.INDUSTRY | 1 | Apr 2, 2026 | clinicaltrials |
| NCT06451497 | This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 100 | Zumutor Biologics Inc.INDUSTRY | 1 | Apr 2, 2026 | clinicaltrials |
| NCT05807776 | Tislelizumab Monotherapy or Combined With Lenvatinib as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma. | completed | Phase 2 | 36 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT06553885 | Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCC | recruiting | Phase 2 | 40 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT02435953 | TACE+RFA Versus TACE Alone for Intermediate-stage Hepatocellular Carcinoma(TORCH) | completed | Phase 3 | 241 | Ming ZhaoOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT03727633 | Hepatocellular Carcinoma on Cirrhosis With Child A/B7 and Hepatic Intra Arterial Injection of Idarubicin/Lipiodol Emulsion(LIDA-BII) | terminated | Phase 2 | 44 | University Hospital, MontpellierOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT06807437 | Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula | recruiting | Phase 3 | 274 | SWOG Cancer Research NetworkNETWORK | 1 | Mar 31, 2026 | clinicaltrials |
| NCT03860272 | Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer | active not recruiting | Phase 1 | 499 | Agenus Inc.INDUSTRY | 2 | Mar 30, 2026 | clinicaltrials |
| NCT04620538 | Volatile Organic Compounds for the Assessment of Liver Disease(VOCAL) | completed | — | 56 | Imperial College LondonOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT05068752 | Phase II Trial of Vemurafenib and Sorafenib in Pancreatic Cancer | completed | Phase 2 | 10 | HonorHealth Research InstituteOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT07144917 | Immunoparalysis After Pancreaticoduodenectomy(ImPaHLA) | recruiting | — | 100 | Hospices Civils de LyonOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT07500220 | Dual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCC(DUET-HCC) | recruiting | Phase 1 / Phase 2 | 30 | Beijing BiotechINDUSTRY | 1 | Mar 30, 2026 | clinicaltrials |
| NCT04234113 | Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors | terminated | Phase 1 | 115 | SOTIO Biotech AGINDUSTRY | 4 | Mar 27, 2026 | clinicaltrials |
| NCT04281290 | Electrochemotherapy of Posterior Resection Surface for Lowering Disease Recurrence Rate in Pancreatic Cancer (PanECT Study)(PanECT) | active not recruiting | N/A | 10 | University Medical Centre LjubljanaOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT05622136 | Dose-escalation of Regorafenib in Advanced Hepatocellular Carcinoma(STRAT-aHCC) | active not recruiting | Phase 2 | 28 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT06311396 | Development of a Neuronal Microscope | completed | N/A | 30 | Fondazione IRCCS Ca' Granda, Ospedale Maggiore PoliclinicoOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT06687941 | A Study to Evaluate the Tolerability, Safety, and PK of AST-201 in Patients With GPC3-positive Advanced Solid Tumors | recruiting | Phase 1 | 70 | Aptamer Sciences, Inc.INDUSTRY | 1 | Mar 27, 2026 | clinicaltrials |
| NCT07324096 | A Screening Program to Improve the Early Detection of Sporadic Pancreatic Cancer in Individuals With a High-Risk of Developing Pancreatic Cancer(AI-PACED) | recruiting | N/A | 100 | Mayo ClinicOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT07331883 | Sintilimab Combined With Bevacizumab Biosimilar as Adjuvant Treatment After Resection of Ruptured Hepatocellular Carcinoma (CLEAR-2) | recruiting | Phase 2 | 35 | Ruijin HospitalOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT07495215 | A Clinical Study on the Safety, Tolerability and Efficacy of Neoantigen-based Personalized mRNA Therapy iNeo-Vac-R01 Plus PD-1 Inhibitor in Adjuvant Treatment of Liver Cancer Post Radical Resection | recruiting | Phase 1 / Phase 2 | 20 | Yinghua XuOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT05024214 | Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors | recruiting | Phase 1 / Phase 2 | 170 | 3D Medicines (Sichuan) Co., Ltd.INDUSTRY | 1 | Mar 25, 2026 | clinicaltrials |
| NCT05039177 | A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies(HERKULES-3) | completed | Phase 1 / Phase 2 | 101 | Erasca, Inc.INDUSTRY | 1 | Mar 25, 2026 | clinicaltrials |
| NCT07493070 | Ultra-stable Iodized Oil-Chemo Embolization Seq Thermal Ablation in Early Liver Ca | active not recruiting | N/A | 30 | Fujian Medical University Union HospitalOTHER | 1 | Mar 25, 2026 | clinicaltrials |
| NCT07493421 | To Evaluate the Feasibility and Safety of Combining Surgery (Pancreatectomy and Cytoreduction) With HIPEC for Treating Pancreatic Cancer With Peritoneal Involvement. | recruiting | N/A | 20 | Unidade Local de Saúde São JoãoOTHER_GOV | 2 | Mar 25, 2026 | clinicaltrials |
| NCT04003636 | Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)(KEYNOTE-966) | completed | Phase 3 | 1,069 | Merck Sharp & Dohme LLCINDUSTRY | 24 | Mar 24, 2026 | clinicaltrials |
| NCT04008797 | A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor | active not recruiting | Phase 1 / Phase 2 | 301 | Eisai Inc.INDUSTRY | 10 | Mar 24, 2026 | clinicaltrials |
| NCT04903548 | Evaluating the Effects of Selective Treatment Utilizing Flex-dosing for Unresectable HCC With Y90 SIR-Spheres | completed | — | 1 | Methodist Health SystemOTHER | 1 | Mar 24, 2026 | clinicaltrials |
| NCT07489768 | GNB4 and Riplet Gene Methylation Combined Detection Kit for Hepatocellular Carcinoma Recurrence Monitoring(CCGLC-019) | not yet recruiting | — | 162 | Tongji HospitalOTHER | 0 | Mar 24, 2026 | clinicaltrials |
| NCT03753659 | IMMULAB - Immunotherapy With Pembrolizumab in Combination With Local Ablation in Hepatocellular Carcinoma (HCC) | completed | Phase 2 | 30 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT05240040 | Treat Primary and Metastatic Liver Tumors | withdrawn | — | 0 | Methodist Health SystemOTHER | 0 | Mar 23, 2026 | clinicaltrials |
| NCT07089940 | OMO-103 for the Treatment of Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma | recruiting | Early Phase 1 | 12 | OHSU Knight Cancer InstituteOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT07392541 | Adebrelimab Combined With Gemcitabine, Cisplatin, and Simvastatin for Advanced Biliary Tract Cancer | recruiting | Phase 1 / Phase 2 | 29 | Tongji HospitalOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT07466602 | cfDNA Methylation for Liver Cancer Recurrence Detection | recruiting | — | 500 | Wuhan Ammunition Life-tech Co., LtdINDUSTRY | 1 | Mar 23, 2026 | clinicaltrials |
| NCT05191940 | Radiotherapy for Locally Advanced Pancreatic Carcinomas (Phase II Trial)(LAPC) | recruiting | N/A | 30 | EBG MedAustron GmbHINDUSTRY | 1 | Mar 20, 2026 | clinicaltrials |
| NCT06140134 | Liver Transplantation in Intrahepatic Cholangiocarcinoma | recruiting | — | 30 | Rutgers, The State University of New JerseyOTHER | 1 | Mar 20, 2026 | clinicaltrials |
| NCT06345508 | Early Detection of Liver Cancer by QUS(QUS in HCC) | recruiting | — | 328 | Centre hospitalier de l'Université de Montréal (CHUM)OTHER | 1 | Mar 20, 2026 | clinicaltrials |
| NCT04720716 | A Study to Compare the Effectiveness and Safety of IBI310 Combined With Sintilimab Versus Sorafenib in the First-line Treatment of Advanced HCC | completed | Phase 3 | 344 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Mar 19, 2026 | clinicaltrials |
| NCT04862260 | Cholesterol Disruption in Combination With the Standard of Care in Patients With Advanced Pancreatic Adenocarcinoma | active not recruiting | Early Phase 1 | 3 | CHU de Quebec-Universite LavalOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT05411133 | Treatment of Cabotamig (ARB202) in Advanced Gastrointestinal Cancer Patients | completed | Phase 1 | 33 | Arbele Pty LtdINDUSTRY | 2 | Mar 19, 2026 | clinicaltrials |
| NCT05629845 | Prevention of Variceal Rebleeding by EUS-guided vs Conventional Endoscopic Therapy in Hepatocellular Carcinoma Patients(EUS-SPV) | recruiting | N/A | 84 | Chinese University of Hong KongOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT06354387 | Alectinib in Combination With Nivolumab in the Treatment of Recurrent or Refractory HCC Patients Guided With Serum RNase1 and Tumor Expression of PD-L1 | completed | Phase 1 | 5 | China Medical University HospitalOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT07482059 | A Multicenter Clinical Study of Combined Therapy for Unresectable Hepatocellular Carcinoma | recruiting | Phase 1 / Phase 2 | 33 | West China HospitalOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT07483242 | Individualized Surgical Guidance in HCC-BDTT | completed | — | 151 | First Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT06077591 | Prospective Clinical Validation of Next Generation Sequencing (NGS) and Patient-Derived Tumor Organoids (PDO) Guided Therapy in Patients With Advanced/ Inoperable Solid Tumors(PDO) | recruiting | N/A | 40 | Chinese University of Hong KongOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT06599502 | A Phase I/IIa Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD0022 as Monotherapy and in Combination With Anti-cancer Agents in Adult Participants With Tumours Harbouring a KRASG12D Mutation(ALAFOSS-01) | terminated | Phase 1 | 17 | AstraZenecaINDUSTRY | 4 | Mar 18, 2026 | clinicaltrials |
| NCT06648057 | Investigation of Predictive Biomarkers in Patients With Advanced BTC Treated With Lenvatinib Plus Pembrolizumab | recruiting | — | 100 | CHA UniversityOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT07479264 | A Study on Intratumoral Fibrosis and α-SMA Expression in Intrahepatic Cholangiocarcinoma | completed | — | 169 | First Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT07480928 | Dual-Targeting CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma(DUAL-NK-PDAC) | recruiting | Phase 1 / Phase 2 | 42 | Beijing BiotechINDUSTRY | 1 | Mar 18, 2026 | clinicaltrials |
| NCT07481032 | Effect of Fufang Biejiaruangan Combined With Antiviral Therapy on the Incidence of Hepatocellular Carcinoma in Patients With Hepatitis B-related Cirrhosis: A Multicenter, Randomized, Placebo-controlled Study | not yet recruiting | N/A | 1,034 | Nanfang Hospital, Southern Medical UniversityOTHER | 0 | Mar 18, 2026 | clinicaltrials |
Data updated 24 days agoSource updated Apr 2, 2026source: clinicaltrials